Express Mail Label No. EV668455514US

Date of Deposit: September 15, 2006

## **Listing of Claims**

- 1. (Original) A method for the isolation of prostate stem cells comprising the selective enrichment of prostate stem cells which express CD133 antigen.
- 2. (Original) A method according to Claim 1 wherein said stem cells also express high levels of  $\alpha_2\beta_1$  integrin.
- 3. (Currently Amended) A method according to Claim 1 or 2 wherein said selective enrichment comprises the following steps:
  - i) providing a cell preparation comprising prostate cells derived from prostate tissue;
  - ii) providing cell culture conditions which allow the maintenance of said prostate cells in culture and the binding of said prostate cells to a collagen based matrix;
  - iii) selecting said bound cells wherein said cells express CD133 antigen.
  - 4. A method according to Claim 3 wherein said method includes the additional steps of:
  - i) culturing cells which express CD133 antigen in culture medium comprising granulocyte macrophage colony stimulating factor (GM-CSF), stem cell factor (SCF) and leukaemia inhibitory factor (LIF); and
  - ii) passaging the selected cells in (i) in a serum free medium.
  - 5. (Currently Amended) A method according to any of Claims 1-4 Claim 3 wherein said selected cells express epithelial antigen.
- 6. (Original) A method according to Claim 5 wherein said antigen is human epithelial antigen.
- 7. (Currently Amended) A method according to any of Claims 1-6-Claim 3 wherein said selected cells express CD44 antigen.
- 8. (Currently Amended) A method according to any of Claims 1-7 Claim 3 wherein said prostate derived tissue comprises cancerous prostate cells.

- 9. (Currently Amended) A method according to Claim 8 wherein said cancerous prostate cells are derived from metastatic prostate derived tissue.
- 10. (Currently Amended) A method according to Claim [[9]] 8 wherein said cancerous prostate cells are derived from a primary and metastic prostate tumours tumour.
- 11. (Currently Amended) A method according to any of Claims 1-10 Claim 3 wherein said collagen based matrix comprises collagen I.
- 12. (Currently Amended) A prostate stem cell obtainable by the method of Claim 1 according to any of Claims 1-11.
- 13. (Original) A prostate stem cell according to Claim 12 wherein said cell is a prostate cancer stem cell.
  - 14. (Original) A prostate stem cell according to Claim 13 wherein said stem cell is cloned.
- 15. (Original) A cell culture of substantially pure prostate stem cells wherein said cells express CD133 antigen.
  - 16. (Currently Amended) A <u>cell</u> culture according to Claim 15 wherein said <del>cloned</del> cells are prostate cancer stem cells.
- 17. (Currently Amended) A <u>cell</u> culture according to Claim 16 wherein said <u>prostate cancer</u> stem cells express high levels of  $\alpha_2\beta_1$  integrin.
- 18. (Currently Amended) A <u>cell</u> culture according to Claim 16 <del>or 17</del> wherein said <u>prostate</u> cancer stem cells express epithelial antigen.
- 19. (Currently Amended) A <u>cell\_culture according to Claim 18</u> wherein said epithelial antigen is human epithelial antigen.
- 20. (Currently Amended) A <u>cell</u> culture according to <u>any of Claims 16-19 Claim 16</u> wherein <u>said prostate cancer stem</u> cells express CD44 antigen.

Express Mail Label No. EV668455514US Date of Deposit: September 15, 2006

21. (Currently Amended) A culture according to Claim 16 wherein said <u>prostate cancer stem</u> cells express CD133 antigen, high levels of  $\alpha_2\beta_1$  integrin, human epithelial antigen and CD44 antigen.

Claims 22-74 (Canceled)